Escitalopram (Lexapro) is being evaluated for its efficacy in treating major depressive disorder in patients with comorbid Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Given the increasing recognition of mental health issues in chronic neurological conditions, this study addresses an unmet need in the market. The potential to expand Lexapro's indications could enhance its market position against competitors in the antidepressant space, particularly those targeting similar patient populations. The results may influence prescribing practices and reimbursement policies, thereby impacting market access and commercial strategy for the product.